Published in Br J Cancer on October 01, 1995
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer (2007) 1.05
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer (2002) 0.80
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med (1992) 5.14
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med (1990) 4.66
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys (1993) 1.51
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res (1984) 1.43
Acute and cumulative effects of carboplatin on renal function. Br J Cancer (1989) 1.33
The sequence of histological changes in mouse lungs after single doses of x-rays. Int J Radiat Oncol Biol Phys (1980) 1.26
Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol (1988) 1.15
Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev (1985) 1.08
Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol (1989) 1.08
Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys (1979) 0.94
Radiotherapy of squamous, adeno- and large cell carcinoma of the lung. Cancer Treat Rev (1982) 0.93
A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res (1985) 0.88
A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol (1988) 0.87
Dose-dependence of the time of appearance of lung damage in mice given thoracic irradiation. Int J Radiat Biol Relat Stud Phys Chem Med (1982) 0.86
The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. Eur J Cancer Clin Oncol (1988) 0.85
Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys (1991) 0.84
Radiation pneumonitis. Bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am Rev Respir Dis (1993) 0.83
Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis. Eur J Cancer Clin Oncol (1987) 0.82
The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol (1989) 0.82
Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiother Oncol (1987) 0.82
Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study. Int J Radiat Oncol Biol Phys (1986) 0.81
Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep (1987) 0.81
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. J Clin Oncol (1991) 0.79
Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother Oncol (1986) 0.79
Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol (1994) 0.79
The assessment of tumor response to irradiation of lung cancer: continuous versus split-course regimes. Int J Radiat Oncol Biol Phys (1977) 0.77
Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol (1992) 0.77
A kinetic model for the pathogenesis of radiation lung damage. Int J Radiat Biol Relat Stud Phys Chem Med (1982) 0.77
Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse. Int J Radiat Oncol Biol Phys (1987) 0.77
Brief overview of combination chemotherapy in non-small-cell lung cancer. Semin Oncol (1986) 0.76
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res (1993) 1.99
Clozapine-induced agranulocytosis: a case report. Immunopathophysiological considerations. Neth J Med (1998) 1.98
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Chromosomal damage in peripheral blood lymphocytes of patients treated for testicular cancer. Hum Genet (1990) 1.84
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res (1993) 1.81
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer (1980) 1.52
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol (2004) 1.52
Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis (2001) 1.52
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Br J Surg (2001) 1.51
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) (1992) 1.43
Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res (2000) 1.42
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer (1995) 1.40
Endodermal sinus tumor of the ovary during pregnancy: a case report. Am J Obstet Gynecol (1991) 1.40
[Good results with liver resection for colorectal liver metastases]. Ned Tijdschr Geneeskd (1995) 1.40
[Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin]. Ned Tijdschr Geneeskd (1991) 1.38
The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev (2000) 1.37
Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother (1981) 1.37
Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med (1997) 1.35
Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther (1999) 1.34
Acute and cumulative effects of carboplatin on renal function. Br J Cancer (1989) 1.33
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1990) 1.33
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol (1984) 1.23
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther (2006) 1.22
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res (1992) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Surface roughness, porosity and wettability of gentamicin-loaded bone cements and their antibiotic release. Biomaterials (2000) 1.20
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol (1999) 1.17
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst (1989) 1.16
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol (1989) 1.16
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res (1992) 1.14
Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol (1999) 1.14
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol (1995) 1.10
Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer (1983) 1.09
High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta (1993) 1.09
Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res (1988) 1.08
Validity and reliability of self-reported exposure to environmental tobacco smoke in work offices. J Occup Environ Med (1997) 1.08
Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci U S A (1992) 1.08
Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr (1994) 1.07
Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. Br J Cancer (2000) 1.07
Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology (1999) 1.05
Electrochemical and surface characterization of a nickel-titanium alloy. Biomaterials (1998) 1.05
Combined in vitro modulation of adriamycin resistance. Int J Cancer (1991) 1.04
Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl (2000) 1.03
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet (1991) 1.02
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res (1998) 1.02
Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma. Eur J Cancer Clin Oncol (1986) 1.01
Ophthalmic toxicity following paclitaxel infusion. Ann Oncol (1997) 1.00
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer (1995) 1.00
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol (1999) 1.00
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer (1996) 1.00
Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med (1992) 1.00
Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg (1991) 0.99
Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem (2000) 0.99